Lapatinib is an oral small-molecule inhibitor of the EGFR and ErbB2 (HER2) tyrosine kinase receptors.
The company seeks the approval for Tyverb as a treatment for the patients who are suffering from metastatic breast cancer whose tumours over-express HER2 (ErbB2).
So far, GSK has received approval for Tyverb/Tykerb in 90 countries including the EU, Switzerland, US, Canada, Japan, Australia and countries in South America and Asia.